PRKAR1A and the evolution of pituitary tumors

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 3-7

  Kirschner, Lawrence S ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Carney complex; Mouse models; Pituitary tumorigenesis; PRKAR1A; Protein kinase A

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MESSENGER RNA; PROLACTIN; PROTEIN PRKAR1A; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; CARNEY COMPLEX; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SIGNAL TRANSDUCTION;

ACROMEGALY; ANIMALS; CARNEY COMPLEX; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MICE; MYXOMA; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; SOMATOTROPHS;

EID: 77955324701     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.04.027     Document Type: Review

References (50)

1. Almeida M.Q., Muchow M., Boikos S., Bauer A.J., Griffin K.J., Tsang K.M., Cheadle C., Watkins T., Wen F., Starost M.F., Bossis I., Nesterova M., Stratakis C.A. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum. Mol. Genet. 2010, 19:1387-1398.
2. Amieux P.S., Howe D.G., Knickerbocker H., Lee D.C., Su T., Laszlo G.S., Idzerda R.L., McKnight G.S. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J. Biol. Chem. 2002, 277:27294-27304.
3. Armstrong D.K., Irvine A.D., Handley J.M., Walsh M.Y., Hadden D.R., Bingham E.A. Carney complex: report of a kindred with predominantly cutaneous manifestations. Br. J. Dermatol. 1997, 136:578-582.
4. Ben-Jonathan N., Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 2001, 22:724-763.
5. Bertherat J. Carney complex (CNC). Orphanet. J. Rare Dis. 2006, 1:1-6.
6. Bertherat J., Horvath A., Groussin L., Grabar S., Boikos S., Cazabat L., Libe R., Rene-Corail F., Stergiopoulos S., Bourdeau I., Bei T., Clauser E., Calender A., Kirschner L.S., Bertagna X., Carney J.A., Stratakis C.A. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 2009, 94:2085-2091.
7. Boikos S.A., Stratakis C.A. Carney complex: the first 20 years. Curr. Opin. Oncol. 2007, 19:24-29.
8. Bossis I., Voutetakis A., Matyakhina L., Pack S., Abu-Asab M., Bourdeau I., Griffin K.J., Courcoutsakis N., Stergiopoulos S., Batista D., Tsokos M., Stratakis C.A. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J. Med. Genet. 2004, 41:596-600.
9. Burton F.H., Hasel K.W., Bloom F.E., Sutcliffe J.G. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 1991, 350:74-77.
10. Carney J.A. Carney complex: the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Semin. Dermatol. 1995, 14:90-98.
11. Carney J.A., Gordon H., Carpenter P.C., Shenoy B.V., Go V.L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985, 64:270-283.
12. Cazabat L., Guillaud-Bataille M., Bertherat J., Raffin-Sanson M.L. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm. Res. 2009, 71:132-141.
13. Griffin K.J., Kirschner L.S., Matyakhina L., Stergiopoulos S., Robinson-White A., Lenherr S., Weinberg F.D., Claflin E., Meoli E., Cho-Chung Y.S., Stratakis C.A. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res. 2004, 64:8811-8815.
14. Horvath A., Boikos S., Giatzakis C., Robinson-White A., Groussin L., Griffin K.J., Stein E., Levine E., Delimpasi G., Hsiao H.P., Keil M., Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S., Cramer K., Gaillard R.C., Bertagna X., Carney J.A., Bertherat J., Bossis I., Stratakis C.A. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 2006, 38:794-800.
15. Horvath A., Giatzakis C., Tsang K., Greene E., Osorio P., Boikos S., Libe R., Patronas Y., Robinson-White A., Remmers E., Bertherat J., Nesterova M., Stratakis C.A. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur. J. Hum. Genet. 2008, 16:1245-1253.
16. Kaltsas G.A., Kola B., Borboli N., Morris D.G., Gueorguiev M., Swords F.M., Czirjak S., Kirschner L.S., Stratakis C.A., Korbonits M., Grossman A.B. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin. Endocrinol. (Oxf.) 2002, 57:443-448.
17. Kineman R.D., Teixeira L.T., Amargo G.V., Coschigano K.T., Kopchick J.J., Frohman L.A. The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling. Endocrinology 2001, 142:3764-3773.
18. Kirschner L.S., Taymans S.E., Pack S., Pak E., Pike B.L., Chandrasekharappa S.C., Zhuang Z., Stratakis C.A. Genomic mapping of chromosomal region 2p15-p21 (D2S378-D2S391): integration of Genemap'98 within a framework of yeast and bacterial artificial chromosomes. Genomics 1999, 62:21-33.
19. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., Cho-Chung Y.S., Stratakis C.A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat. Genet. 2000, 26:89-92.
20. Kirschner L.S., Sandrini F., Monbo J., Lin J.P., Carney J.A., Stratakis C.A. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum. Mol. Genet. 2000, 9:3037-3046.
21. Kirschner L.S., Kusewitt D.F., Matyakhina L., Towns W.H., Carney J.A., Westphal H., Stratakis C.A. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 2005, 65:4506-4514.
22. Kirschner L.S., Yin Z., Jones G.N., Mahoney E. Mouse models of altered protein kinase A signaling. Endocr. Relat. Cancer 2009, 16:773-793.
23. Lania A.G., Mantovani G., Ferrero S., Pellegrini C., Bondioni S., Peverelli E., Braidotti P., Locatelli M., Zavanone M.L., Ferrante E., Bosari S., Beck-Peccoz P., Spada A. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res. 2004, 64:9193-9198.
24. Le Y., Sauer B. Conditional gene knockout using cre recombinase. Methods Mol. Biol. 2000, 136:477-485.
25. Lin B.C., Sullivan R., Lee Y., Moran S., Glover E., Bradfield C.A. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Biol. Chem. 2007, 282:35924-35932.
26. Luque R.M., Soares B.S., Peng X.D., Krishnan S., Cordoba-Chacon J., Frohman L.A., Kineman R.D. Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation. Endocrinology 2009, 150:3177-3185.
27. Mantovani G., Bondioni S., Ferrero S., Gamba B., Ferrante E., Peverelli E., Corbetta S., Locatelli M., Rampini P., Beck-Peccoz P., Spada A., Lania A.G. Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 2005, 90:6721-6724.
28. Matsubara S., Sato M., Mizobuchi M., Niimi M., Takahara J. Differential gene expression of growth hormone (GH)-releasing hormone (GRH) and GRH receptor in various rat tissues. Endocrinology 1995, 136:4147-4150.
29. Mayo K.E., Godfrey P.A., Suhr S.T., Kulik D.J., Rahal J.O. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog. Horm. Res. 1995, 50:35-73.
30. Nadella K.S., Kirschner L.S. Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res. 2005, 65:10307-10315.
31. Oesch-Bartlomowicz B., Huelster A., Wiss O., Antoniou-Lipfert P., Dietrich C., Arand M., Weiss C., Bockamp E., Oesch F. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9218-9223.
32. Pack S.D., Kirschner L.S., Pak E., Zhuang Z., Carney J.A., Stratakis C.A. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Clin. Endocrinol. Metab. 2000, 85:3860-3865.
33. Pack S.D., Qin L.X., Pak E., Wang Y., Ault D.O., Mannan P., Jaikumar S., Stratakis C.A., Oldfield E.H., Zhuang Z., Weil R.J. Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 2005, 43:72-82.
34. Pavel E., Nadella K., Towns W.H., Kirschner L.S. Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol. Endocrinol. 2008, 22:430-440.
35. Raff S.B., Carney J.A., Krugman D., Doppman J.L., Stratakis C.A. Prolactin secretion abnormalities in patients with the "syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Pediatr. Endocrinol. Metab. 2000, 13:373-379.
36. Sandrini F., Kirschner L.S., Bei T., Farmakidis C., Yasufuku-Takano J., Takano K., Prezant T.R., Marx S.J., Farrell W.E., Clayton R.N., Groussin L., Bertherat J., Stratakis C.A. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J. Med. Genet. 2002, 39:e78.
37. Stergiopoulos S.G., Abu-Asab M.S., Tsokos M., Stratakis C.A. Pituitary pathology in Carney complex patients. Pituitary 2004, 7:73-82.
38. Stratakis C.A., Carney J.A., Lin J.P., Papanicolaou D.A., Karl M., Kastner D.L., Pras E., Chrousos G.P. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J. Clin. Invest. 1996, 97:699-705.
39. Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 2001, 86:4041-4046.
40. Sun Y., Lu X., Gershengorn M.C. Thyrotropin-releasing hormone receptors-similarities and differences. J. Mol. Endocrinol. 2003, 30:87-97.
41. Teixeira L.T., Kiyokawa H., Peng X.D., Christov K.T., Frohman L.A., Kineman R.D. p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation. Oncogene 2000, 19:1875-1884.
42. Veugelers M., Wilkes D., Burton K., McDermott D.A., Song Y., Goldstein M.M., La Perle K., Vaughan C.J., O'Hagan A., Bennett K.R., Meyer B.J., Legius E., Karttunen M., Norio R., Kaariainen H., Lavyne M., Neau J.P., Richter G., Kirali K., Farnsworth A., Stapleton K., Morelli P., Takanashi Y., Bamforth J.S., Eitelberger F., Noszian I., Manfroi W., Powers J., Mochizuki Y., Imai T., Ko G.T., Driscoll D.A., Goldmuntz E., Edelberg J.M., Collins A., Eccles D., Irvine A.D., McKnight G.S., Basson C.T. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14222-14227.
43. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., Tuppurainen K., Ebeling T.M., Salmela P.I., Paschke R., Gundogdu S., De Menis E., Makinen M.J., Launonen V., Karhu A., Aaltonen L.A. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
44. Watson J.C., Stratakis C.A., Bryant-Greenwood P.K., Koch C.A., Kirschner L.S., Nguyen T., Carney J.A., Oldfield E.H. Neurosurgical implications of Carney complex. J. Neurosurg. 2000, 92:413-418.
45. Weinstein L.S., Yu S., Warner D.R., Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr. Rev. 2001, 22:675-705.
46. Wilkes D., McDermott D.A., Basson C.T. Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol. 2005, 6:501-508.
47. Yamasaki H., Mizusawa N., Nagahiro S., Yamada S., Sano T., Itakura M., Yoshimoto K. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24. Clin. Endocrinol. (Oxf.) 2003, 58:464-470.
48. Yin Z., Williams-Simons L., Rawahneh L., Asa S., Kirschner L.S. Development of a pituitary-specific cre line targeted to the Pit-1 lineage. Genesis 2008, 46:37-42.
49. Yin Z., Williams-Simons L., Parlow A.F., Asa S., Kirschner L.S. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol. Endocrinol. 2008, 22:380-387.
50. Yin Z., Jones G.N., Towns W.H., Zhang X., Abel E.D., Binkley P.F., Jarjoura D., Kirschner L.S. Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 2008, 117:1414-1422.